{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:09:19Z","timestamp":1784282959420,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["DGOS-INCA-46644"],"award-info":[{"award-number":["DGOS-INCA-46644"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BPI financement European community","award":["E8983-PREDICTIV"],"award-info":[{"award-number":["E8983-PREDICTIV"]}]},{"name":"Agence national de la recherche","award":["ANR Labex DEvweCAN 10-LABX-0061"],"award-info":[{"award-number":["ANR Labex DEvweCAN 10-LABX-0061"]}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020549","name":"Centre Leon Berard","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020549","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EURACAN 739521"],"award-info":[{"award-number":["EURACAN 739521"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12032-021-01536-4","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:02:44Z","timestamp":1636106564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-3711","authenticated-orcid":false,"given":"Alice","family":"Bonneville-Levard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Frappaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Lavergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Corset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Agrapart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pissaloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Attignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Cartalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Thomas-Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meyronet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Taillandier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Blonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Viari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sohier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Paindavoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Treilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"issue":"2","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"issue":"24","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1158\/1078-0432.CCR-06-0627","volume":"12","author":"R Rosell","year":"2006","unstructured":"Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res. 2006;12(24):7222\u201331.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"8","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/gb-2011-12-8-125","volume":"12","author":"A Sboner","year":"2011","unstructured":"Sboner A, Mu XJ, Greenbaum D, Auerbach RK, Gerstein MB. The real cost of sequencing: higher than you think! Genome Biol. 2011;12(8):125.","journal-title":"Genome Biol"},{"issue":"3","key":"1536_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41431-017-0081-3","volume":"26","author":"P Marino","year":"2018","unstructured":"Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, et al. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet. 2018;26(3):314\u201323.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"28","key":"1536_CR8","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1200\/JCO.2015.61.1525","volume":"33","author":"MM Gounder","year":"2015","unstructured":"Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, et al. Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors. J Clin Oncol. 2015;33(28):3186\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/annonc\/mdz080","volume":"30","author":"O Tredan","year":"2019","unstructured":"Tredan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardiere A, Fayette J, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol. 2019;30(5):757\u201365.","journal-title":"Ann Oncol"},{"issue":"D1","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","volume":"44","author":"NA O\u2019Leary","year":"2016","unstructured":"O\u2019Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016;44(D1):D733\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1536_CR11","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777\u201383.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308\u201311.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/neuonc\/noy024","volume":"20","author":"S Baskaran","year":"2018","unstructured":"Baskaran S, Mayrhofer M, Kultima HG, Bergstrom T, Elfineh L, Cavelier L, et al. Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages. Neuro-Oncol. 2018;20(8):1080\u201391.","journal-title":"Neuro-Oncol"},{"issue":"7","key":"1536_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/carcin\/bgy052","volume":"39","author":"X Chen","year":"2018","unstructured":"Chen X, Wen Q, Stucky A, Zeng Y, Gao S, Loudon WG, et al. Relapse pathway of glioblastoma revealed by single-cell molecular analysis. Carcinogenesis. 2018;39(7):931\u20136.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"a000570","DOI":"10.1101\/mcs.a000570","volume":"1","author":"J Laskin","year":"2015","unstructured":"Laskin J, Jones S, Aparicio S, Chia S, Ch\u2019ng C, Deyell R, et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud. 2015;1(1):a000570.","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"13","key":"1536_CR16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"TC Le","year":"2015","unstructured":"Le TC, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324\u201334.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1536_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/neuonc\/nox216","volume":"20","author":"E Pfaff","year":"2018","unstructured":"Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, et al. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT neuro master match (N2M2) pilot study. Neuro-Oncol. 2018;20(6):826\u201337.","journal-title":"Neuro-Oncol"},{"issue":"11","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/neuonc\/nox085","volume":"19","author":"JM Figueroa","year":"2017","unstructured":"Figueroa JM, Skog J, Akers J, Li H, Komotar R, Jensen R, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncol. 2017;19(11):1494\u2013502.","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/neuonc\/nop015","volume":"12","author":"JJ Raizer","year":"2010","unstructured":"Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncol. 2010;12(1):95\u2013103.","journal-title":"Neuro-Oncol"},{"issue":"10","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/neuonc\/noq072","volume":"12","author":"WK Yung","year":"2010","unstructured":"Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncol. 2010;12(10):1061\u201370.","journal-title":"Neuro-Oncol"},{"issue":"8","key":"1536_CR21","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","volume":"27","author":"MJ van den Bent","year":"2009","unstructured":"van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268\u201374.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","volume":"20","author":"E Eskilsson","year":"2018","unstructured":"Eskilsson E, Rosland GV, Solecki G, Wang Q, Harter PN, Graziani G, et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro-Oncol. 2018;20(6):743\u201352.","journal-title":"Neuro-Oncol"},{"issue":"4","key":"1536_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00520-020-05663-y","volume":"29","author":"D Frappaz","year":"2021","unstructured":"Frappaz D, Bonneville-Levard A, Ricard D, Carrie S, Schiffler C, Xuan KH, et al. Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias. Support Care Cancer. 2021;29(4):1883\u201391.","journal-title":"Support Care Cancer"},{"issue":"10","key":"1536_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373\u201385.","journal-title":"Lancet Oncol"},{"issue":"34","key":"1536_CR25","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","volume":"26","author":"PD Brown","year":"2008","unstructured":"Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1536_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","volume":"80","author":"JH Uhm","year":"2011","unstructured":"Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"35","key":"1536_CR27","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36(35):3477\u201384.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1536_CR28","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol. 2020;22(8):1073\u2013113.","journal-title":"Neuro-Oncol"},{"issue":"3","key":"1536_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/neup.12459","volume":"38","author":"T Furuta","year":"2018","unstructured":"Furuta T, Miyoshi H, Komaki S, Arakawa F, Morioka M, Ohshima K, et al. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Neuropathology. 2018;38(3):218\u201327.","journal-title":"Neuropathology"},{"key":"1536_CR30","doi-asserted-by":"crossref","unstructured":"Frappaz D, Sunyach MP, Le RE, Blonski M, Laurence V, Bonneville LA, et al. Adolescent and Young Adults (AYAS) brain tumor national Web conference. On behalf of ANOCEF, GO-AJA and SFCE societies. Bull Cancer. 2016;103(12):1050\u20136.","DOI":"10.1016\/j.bulcan.2016.10.010"},{"issue":"24","key":"1536_CR31","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33(24):2646\u201354.","journal-title":"J Clin Oncol"},{"key":"1536_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab087","author":"D Frappaz","year":"2021","unstructured":"Frappaz D, Barritault M, Montane L, Laigle-Donadey F, Chinot O, Le Rhun E, et al. MEVITEM\u2014a phase I\/II of vismodegib + temozolomide vs temozolomide in patients with recurrent\/refractory medulloblastoma with Sonic Hedgehog pathway activation. Neuro-Oncol. 2021. https:\/\/doi.org\/10.1093\/neuonc\/noab087.","journal-title":"Neuro-Oncol"},{"issue":"29","key":"1536_CR33","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1536_CR34","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1073\/pnas.1217602110","volume":"110","author":"A Iwanami","year":"2013","unstructured":"Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci USA. 2013;110(11):4339\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1536_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-015-1432-1","volume":"129","author":"K Aldape","year":"2015","unstructured":"Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):829\u201348.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"1536_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"9","key":"1536_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943\u201353.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1536_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-019-5413-y","volume":"19","author":"P Lesueur","year":"2019","unstructured":"Lesueur P, Lequesne J, Grellard JM, Dugue A, Coquan E, Brachet PE, et al. Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019;19(1):198.","journal-title":"BMC Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01536-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01536-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01536-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T07:47:48Z","timestamp":1642060068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01536-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01536-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study received local approval (Ethics committee of Lyon Sud-Est IV) and was conducted in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonization, and the Declaration of Helsinki, and relevant French and European laws and directives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors wrote, have read, and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"4"}}